Clinical trials: MuSK Myasthenia Gravis
Myasthenia Gravis, Myasthenia Gravis, MuSK
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID)…
- Trial name
- SYNAPSE-MG (NCT06414954)
- Testing
- NMD670
- Where
- 40 sites in United States, Belgium and 8 more
- Volunteers
- 84 people
- Sponsor
- NMD Pharma A/S
Myasthenia Gravis (MG), Myasthenia Gravis, Generalized
AXIS MG Patient Registry
The goal of the AXIS Autoimmune Neurology Registry is to learn about the experiences of adults living with autoimmune neurological disorders, starting with myasthenia gravis (MG), over time.
- Conditions
- Myasthenia Gravis (MG), Myasthenia Gravis, Generalized, Myasthenia Gravis, Ocular, Myasthenia Gravis Crisis
- Trial name
- AXIS (NCT07761026)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Autoimmune Neurology Alliance
Myasthenia Gravis, MuSK MG
MuSK Myasthenia 1000 Study
The MuSK myasthenia gravis 1000 study seeks to collect saliva samples from 1000 subjects with laboratory confirmed diagnosis of MuSK myasthenia to identify genetic variations associated with MuSK MG.
- Conditions
- Myasthenia Gravis, MuSK MG, MuSK Myasthenia Gravis
- Trial name
- MuSK 1000 (NCT06259071)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- George Washington University
Myasthenia Gravis, Generalized Myasthenia
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
- Conditions
- Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
- Trial name
- NCT06106672
- Testing
- CNP-106
- Where
- 17 sites in United States
- Volunteers
- 54 people
- Sponsor
- COUR Pharmaceutical Development Company, Inc.
MuSK Myasthenia Gravis
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis
Muscle-specific tyrosine kinase (MuSK) myasthenia gravis (MG) is a rare but potentially severe disease, in which patients develop pathogenic autoantibodies that specifically target the MuSK protein in the neuromuscular junction.
- Trial name
- NCT05451212
- Testing
- MuSK-CAART
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Cabaletta Bio
Myasthaenia Gravis, Myasthenia
Myasthenia Gravis Foundation of America Global MG Patient Registry
The goal of this observational study is to learn about the experiences of people living with Myasthenia Gravis (MG) in the United States.
- Conditions
- Myasthaenia Gravis, Myasthenia, Myasthenia Gravis Associated with Thymoma, Myasthenia Gravis Crisis
- Trial name
- MGFAPR (NCT06617741)
- Where
- United States
- Volunteers
- 3,800 people
- Sponsor
- Myasthenia Gravis Foundation of America
Myasthenia Gravis, MuSK, AChR Myasthenia Gravis
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
Evaluate the long-term safety of amifampridine phosphate in patients with MuSK antibody positive and AChR antibody positive myasthenia gravis.
- Trial name
- NCT03579966
- Testing
- Amifampridine Phosphate
- Where
- 3 sites in United States, Italy
- Volunteers
- 63 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.